METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Clinical trials for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail targets tough pancreatic tumors
Disease control Not yet recruitingThis early-stage trial tests whether combining two drugs—selumetinib and DS-8201a—can safely shrink or control advanced pancreatic cancer that has a specific genetic change (KRAS mutation) and a protein called HER2. About 31 adults with cancer that cannot be removed by surgery or…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental vaccine combo takes on tough pancreatic cancer
Disease control Not yet recruitingThis early-phase trial tests a new peptide nanovaccine (ONVAX-01) together with an anti-PD-1 antibody and standard chemotherapy in 9 people with advanced pancreatic cancer that has worsened after prior treatment. The main goals are to see if the combination is safe and whether it…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New hope for tough pancreatic cancer? drug combo targets KRAS mutations
Disease control Not yet recruitingThis study tests a new drug called JAB-23E73, which targets KRAS gene changes, combined with two standard chemotherapies (nab-paclitaxel and gemcitabine) in people whose pancreatic cancer has spread and who haven't had prior treatment. The goal is to see if the combination is saf…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Migraine drug takes on pancreatic cancer in early trial
Disease control Not yet recruitingThis early-phase trial tests whether adding the migraine drug rimegepant to standard chemotherapy can help people with metastatic pancreatic cancer. About 30 adults who have not had prior treatment will receive the combination. Researchers will track how long the cancer stays und…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Xiuchao Wang • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Heat therapy gives new hope for advanced pancreatic cancer patients
Disease control Not yet recruitingThis study tests whether adding a heat-based treatment called radiofrequency ablation (RFA) to a standard procedure (ERCP) can help people with advanced pancreatic cancer that has spread to the liver live longer. About 178 adults with limited liver spread will be randomly assigne…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: NA • Sponsor: Roberto Valente • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New cocktail of drugs takes on tough pancreatic cancer
Disease control Not yet recruitingThis Phase III trial is testing whether adding the experimental drug chiauranib and an immunotherapy (toripalimab) to standard chemotherapy can help people with metastatic pancreatic cancer live longer. About 558 participants will be randomly assigned to receive either the full c…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE3 • Sponsor: Chipscreen Biosciences, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for tough pancreatic cancer? early trial combines two drugs
Disease control Not yet recruitingThis early-phase trial tests two drugs (cosibelimab and balixafortide) together in people with advanced pancreatic cancer that has stopped responding to standard chemotherapy. The main goal is to find the safest dose and check for side effects. About 24 adults will take part in t…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: Arsen Osipov • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New study tests if tumor genes and organoids can outsmart pancreatic cancer
Knowledge-focused Not yet recruitingThis observational study will enroll 185 people with metastatic pancreatic cancer to see if analyzing tumor genes and lab-grown organoids can predict which standard chemotherapy regimens work best. Researchers will compare predicted drug sensitivity to actual patient outcomes. Th…
Matched conditions: METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA
Sponsor: Prof. Dr. med. Dres. h.c. Jan Schmidt, MME • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC